Amylin and Analogs in Treating Obesity and Metabolic Disorders

Abstract

This study investigates the potential of amylin, a hormone co-secreted with insulin, in the treatment of obesity and metabolic disorders. By analyzing existing research and clinical trial data, the study explores amylin’s mechanisms of action, including its ability to slow gastric emptying, inhibit glucagon secretion, and promote satiety. The study also evaluates the safety and side effects of amylin analogs, particularly pramlintide, and compares them with GLP-1 receptor agonists. Comparative studies with GLP-1 receptor agonists highlight the complementary roles of these therapies, suggesting the possibility of synergistic treatment strategies. Despite common gastrointestinal side effects, amylin analogs are generally well-tolerated and have a favorable safety profile. The findings indicate that amylin and its analogs show promise in managing obesity and metabolic disorders, offering a new therapeutic avenue with a generally favorable safety profile. Future research is needed to develop improved analogs and further explore the clinical applications of amylin in metabolic health.